Dilemmas of recurrent ocular inflammatory disease on immunosuppression and corona virus disease vaccination

Ocular inflammation and corona virus disease vaccination

Authors

  • Srinivasan Sanjay Department of Uveitis and Ocular immunology, Narayana Nethralaya, Bangalore, India
  • Sathi Devi AV Department of Glaucoma, Narayana Nethralaya, Bangalore, India
  • Sharath Kumar Optima Arthritis and Rheumatology Clinic, Bangalore, India
  • Ankush Kawali Department of Uveitis and Ocular immunology, Narayana Nethralaya, Bangalore, India
  • Padmamalini Mahendradas Department of Uveitis and Ocular immunology, Narayana Nethralaya, Bangalore, India

DOI:

https://doi.org/10.15305/ijrci/v11i1/378

Abstract

The current study explores the occurrence of ophthalmic manifestations following coronavirus disease-19 (COVID-19) vaccination. The study discusses the case of a 72-year-old Indian male, who received oral methotrexate for ocular inflammation (recurrent post-operative uveitis with pseudoexfoliative glaucoma) and two doses of COVISHIELD™ vaccine and a booster in 2022. While he discontinued methotrexate for 2 weeks after the first dose, he continued the medication during the second and booster doses. Subsequently, he experienced mild ocular inflammation two weeks after the first dose, one day after the second dose, and one week after the booster dose. Topical steroids effectively controlled the inflammation, and an increased oral methotrexate dosage was used after the second dose. The study highlights the potential for autoimmune inflammatory syndrome following vaccination, although a definite causal link cannot be established. Nonetheless, the presence of side effects should not discourage individuals from receiving vaccinations.

Downloads

Published

31-07-2023

Issue

Vol. 11 No. 1 (2023)

Section

Reviews

License

Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.